vs
Side-by-side financial comparison of Drugs Made In America Acquisition II Corp. (DMII) and Innventure, Inc. (INV). Click either name above to swap in a different company.
Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) focused on pursuing business combination opportunities with U.S.-based pharmaceutical, biotechnology and medical product manufacturing firms, with a core priority of supporting domestic healthcare supply chain stability.
Innventure, Inc. is a business development and commercialization firm that partners with large global corporations to turn their underutilized intellectual property and unused R&D innovations into scalable, high-growth independent businesses. It focuses on sectors including sustainability, advanced materials and life sciences, serving primarily North American and European markets.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $822.0K | ||
| Q3 25 | — | $534.0K | ||
| Q2 25 | — | $476.0K | ||
| Q1 25 | — | $224.0K | ||
| Q3 24 | — | $317.0K |
| Q4 25 | — | $-37.8M | ||
| Q3 25 | — | $-28.3M | ||
| Q2 25 | — | $-84.2M | ||
| Q1 25 | — | $-143.0M | ||
| Q3 24 | — | $-2.2M |
| Q4 25 | — | -1315.8% | ||
| Q3 25 | — | -676.6% | ||
| Q2 25 | — | -501.1% | ||
| Q1 25 | — | 17.9% | ||
| Q3 24 | — | -145.1% |
| Q4 25 | — | -3859.1% | ||
| Q3 25 | — | -5469.1% | ||
| Q2 25 | — | -29952.5% | ||
| Q1 25 | — | -116606.3% | ||
| Q3 24 | — | -4313.6% |
| Q4 25 | — | -4593.8% | ||
| Q3 25 | — | -5305.6% | ||
| Q2 25 | — | -17694.7% | ||
| Q1 25 | — | -63837.9% | ||
| Q3 24 | — | -697.5% |
| Q4 25 | — | $-0.18 | ||
| Q3 25 | — | $-0.51 | ||
| Q2 25 | — | $-1.60 | ||
| Q1 25 | — | $-3.10 | ||
| Q3 24 | — | $-0.94 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
